General Announcement::CORPORATE PRESENTATION FOR EGM 2021

PROPOSED EXPANSION INTO NEW BUSINESS

IMPORTANT NOTICE

Clearbridge Health Limited (the "Company") is a company listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (the "SGX-ST").

This presentation has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226 (2)(b) and 753 (2) of the SGX-ST Listing Manual Section B: Rules of Catalist.

This presentation has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this presentation, including the correctness of any of the statements or opinions made or reports contained in this presentation.

The contact person for the Sponsor is Mr. David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: [phone].

All statements other than statements of historical facts included in this presentation are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward- looking statements. Further, the Company and the Sponsor disclaim any responsibility to update or revise any forward-looking statements for any reason, even if new information becomes available or other events occur in the future, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

The reader(s) of this presentation should consult his or her own independent professional advisers about the issues discussed herein. Neither this presentation nor any part of its contents may be used, reproduced, disclosed or distributed to any other person without the prior written consent of the Company. The Company does not make any representation or warranty, expressed or implied, as to the accuracy of the information contained herein, and expressly disclaims any and all liability based, in whole or in part, on such information, errors therein or omissions therefrom. The information contained in this presentation has not been independently verified and it is not the intention for this presentation to be a complete or comprehensive analysis of the Company's business, financial position or results of operations.

This presentation does not constitute, or form any part of an offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

The information and opinions provided in this presentation is accurate as at the date of this presentation and are subject to change without notice.	2

PROPOSED EXPANSION

• The Group's existing business has delivered a compound annual growth rate of 401.2% in revenue from S$288,000 in 2017 to S$36,258,000 in 2020
• While remaining committed to the existing business, the Group proposes to expand into the business of investing into various entities in the global healthcare sector which are EBITDA positive or at an inflection point with a clear line of sight to profitability and growing such entities with a view towards eventually exiting (the "Proposed New Business")
• The existing core business will continue to form core sources of income of the Group while the Proposed New Business will adopt an enhanced growth strategy in investing, growing and divesting entities in the healthcare sector

CBMG: Medical Clinics/	Healthcare Systems	Medtech Investments
Centres

Proposed New Business

Distribution of medical services and healthcare products with a focus on patient-centric services and healthcare products

Operates 24 renal care centres in Indonesia, 22 clinical laboratories and other patient care facilities in Indonesia

Strategic interests in

medical technology companies that gives the Group access to new medical products and/or services and unlock value for shareholders

Investing into various entities in the global healthcare sector which are

EBITDA positive or at an inflection point with a clear line of sight to profitability and growing such entities with a view towards eventually exiting

Existing Business ("Core")

Proposed New Business ("Plus")

3

PROPOSED NEW BUSINESS OVERVIEW

INVEST

• Portfolio Companies: entities in the global healthcare sectors which are EBITDA positive or at an inflection point with a clear line of sight to profitability
• Investment size and strategies: majority stake or minority holdings in the form of equity, debt or a hybrid in various structures e.g. joint ventures, partnerships, co-investments,and the formation of strategic alliances with parties in various countries

GROW

• Provide support to the Portfolio Companies' operations and business in various areas e.g. research and development, business
  development, market and commercialization strategies, investment strategy, and financial planning
• Portfolio Companies may leverage on the
  Group's capabilities and networks in the Existing Business to scale their operations and business

DIVEST

• Exit strategies: through mergers and acquisitions, listings on public stock exchanges, trade sales, etc.
• Portfolio Companies with synergistic value may be packaged together to achieve a collective divestment
• Assessment may be made to determine if an entity within the Group should be reclassified between Existing Business and the Proposed New Business with a view to maximise shareholders' value

4

RATIONALE OF EXPANSION

Potential in the Proposed New

Attractive value and opportunities in

Additional revenue stream and

Enhanced shareholders' value

Business

the Proposed New Business

flexibility for the Group

• Enable the Group to better

• Allow the Group to carry out

•

Additional

revenue streams for

• Additional funds generated from

participate

in

the

growth

investments in the development of a

the Group which are likely to

additional

revenue

streams,

prospects

of

the

global

wide array of healthcare products to

include profit margins

derived

which can be channelled towards

healthcare sector

address healthcare needs, including

from its exit from the Portfolio

the

enhancement

of

but not limited to, diagnostic tests

Companies

shareholders' value

over

the

• Create synergies

between

the

for endemic

diseases,

vaccines,

long term

Existing

Business

and

the

pandemic

swabbing

booths,

•

A more

diversified

business

Proposed New Business

personalised

healthcare

test and

portfolio and income base for

products/services,

and

digital

future growth

• Portfolio Companies may also be

healthcare

able to provide

complementary

•

Reduce the Group's reliance on

support

to

enhance

the

its Existing Business for its

performance of

the

Existing

revenue streams

Business

•

Allow the Group to be more

resilient in the face of

challenging times

5